{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:39:24Z","timestamp":1783427964476,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T00:00:00Z","timestamp":1447372800000},"content-version":"vor","delay-in-days":650,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/jto.0000000000000076","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T04:34:05Z","timestamp":1389674045000},"page":"205-213","source":"Crossref","is-referenced-by-count":9,"title":["PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Martin","family":"Reck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Molinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarini Prasad","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckart","family":"Laack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria H.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Visseren-Grul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Gridelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0000000000000076_bib1","author":"NCCN National Comprehensive Cancer Network"},{"key":"10.1097\/JTO.0000000000000076_bib2","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1200\/JCO.2010.34.2774","article-title":"2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"29","author":"Azzoli","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7 Suppl","key":"10.1097\/JTO.0000000000000076_bib3","doi-asserted-by":"crossref","first-page":"vii56","DOI":"10.1093\/annonc\/mds226","article-title":"Guidelines Working Group. . Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Peters","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","article-title":"Maintenance chemotherapy for advanced non\u2013small-cell lung cancer: new life for an old idea","volume":"31","author":"Gerber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib6","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1200\/JCO.2010.31.8162","article-title":"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non\u2013small-cell lung cancer","volume":"29","author":"Brugger","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1097\/JTO.0000000000000076_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib9","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdr125","article-title":"Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy","volume":"23","author":"Coudert","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib11","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","article-title":"Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer","volume":"30","author":"P\u00e9rol","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-10-85","volume":"10","author":"Paz-Ares","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1097\/JTO.0000000000000076_bib13","series-title":"Lung. AJCC Cancer Staging Manual","first-page":"127","author":"Fleming","year":"1997"},{"key":"10.1097\/JTO.0000000000000076_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0000000000000076_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib17","series-title":"Analysis of Binary Data","author":"Cox","year":"1989"},{"key":"10.1097\/JTO.0000000000000076_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1097\/JTO.0000000000000076_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/JTO.0b013e318267cf84","article-title":"Safety, resource use, and quality of life in PARAMOUNT: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer","volume":"7","author":"Gridelli","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2008.17.1405","article-title":"Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer","volume":"27","author":"Fidias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1 Suppl","key":"10.1097\/JTO.0000000000000076_bib21","doi-asserted-by":"crossref","first-page":"226S","DOI":"10.1378\/chest.123.1_suppl.226S","article-title":"American College of Chest Physicians. . Chemotherapeutic management of stage IV non-small cell lung cancer","volume":"123","author":"Socinski","year":"2003","journal-title":"Chest"},{"key":"10.1097\/JTO.0000000000000076_bib22","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/annonc\/mdt123","article-title":"Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)","volume":"24","author":"Obasaju","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JTO.0b013e3181d3504d","article-title":"Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy","volume":"5","author":"Sun","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0000000000000076_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","article-title":"Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial","volume":"52","author":"Brodowicz","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0000000000000076_bib25","doi-asserted-by":"crossref","unstructured":"Belani C. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).Oral presentation presented at the American Society of Clinical Oncology (ASCO) ConferenceJune 4\u20138, 2010Chicago, IL:abstract 7506: slide 17","DOI":"10.1200\/jco.2010.28.15_suppl.7506"},{"key":"10.1097\/JTO.0000000000000076_bib26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/JTO.0b013e3182629e37","article-title":"Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view","volume":"7","author":"Edelman","year":"2012","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641530191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641530191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T04:09:41Z","timestamp":1597378181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641530191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S155608641530191X"],"URL":"https:\/\/doi.org\/10.1097\/jto.0000000000000076","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}